Celldex Therapeutics, Inc. (CLDX)
| Market Cap | 2.44B +39.1% |
| Revenue (ttm) | 158,000 -97.3% |
| Net Income | -300.55M |
| EPS | -4.33 |
| Shares Out | 78.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,329,085 |
| Open | 32.68 |
| Previous Close | 32.59 |
| Day's Range | 30.85 - 32.68 |
| 52-Week Range | 22.10 - 45.14 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 63.07 (+102.99%) |
| Est. Earnings | Nov 9, 2026 |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias,... [Read more]
Financial Performance
In 2025, Celldex Therapeutics's revenue was $1.55 million, a decrease of -77.99% compared to the previous year's $7.02 million. Losses were -$258.76 million, 63.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price target is $63.07, which is an increase of 102.99% from the latest price.
News
Celldex adverse event concerns overblown, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis says the Celldex (CLDX) bear case is trying “death by a thousand cuts.” Concerns are bouncing from one adverse event to another, the analyst tells…
Celldex price target raised to $88 from $70 at Leerink
Leerink analyst Thomas Smith raised the firm’s price target on Celldex (CLDX) to $88 from $70 and keeps an Outperform rating on the shares following the company’s investor call to…
Celldex price target raised to $57 from $50 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Celldex (CLDX) to $57 from $50 and keeps an Overweight rating on the shares. Barzolvolimab demonstrated best-in-disease efficacy in EMBARQ-CSU, while i...
Celldex price target raised to $64 from $42 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Celldex (CLDX) to $64 from $42 and keeps a Buy rating on the shares after the company announced that…
Celldex Therapeutics Transcript: Study result
Barzolvolimab achieved highly significant efficacy in two large phase III CSU studies, with rapid, profound, and durable responses, including in omalizumab-refractory and severe angioedema patients. Safety was favorable and consistent, supporting plans for a 2027 BLA submission.
Celldex Therapeutics Press release: Study result
Celldex Therapeutics issued a press release on September 22, 2026, disclosing material business information to investors.
Celldex Therapeutics Slides: Study result
Celldex Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 22, 2026.
Celldex's skin disease drug meets goals in two late-stage trials
Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.
Celldex’s barzolvolimab meets endpoints in Phase 3 urticaria trial
Celldex (CLDX) reported positive topline results from the company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria, or ...
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary...
Celldex Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Barzolvolimab is advancing through large phase III trials for CSU and related conditions, with a differentiated mechanism targeting mast cells and a strong safety profile. The company is preparing for commercial launch, expanding its pipeline, and expects market growth as new therapies accelerate diagnosis and treatment.
Celldex price target raised to $50 from $46 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Celldex (CLDX) to $50 from $46 and keeps an Overweight rating on the shares ahead of topline data from…
Celldex to Present at Upcoming Investor Conference
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Septe...
Celldex price target raised to $46 from $40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Celldex (CLDX) to $46 from $40 and keeps an Overweight rating on the shares.
Celldex price target raised to $53 from $48 at Barclays
Barclays raised the firm’s price target on Celldex (CLDX) to $53 from $48 and keeps an Overweight rating on the shares post the Q2 report. The firm is positive on…
Celldex Therapeutics Earnings release: Q2 2026
Celldex Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Celldex Therapeutics Quarterly report: Q2 2026
Celldex Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Celldex Therapeutics Slides: Corporate presentation
Celldex Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Celldex price target raised to $72 from $48 at Wells Fargo
Wells Fargo raised the firm’s price target on Celldex (CLDX) to $72 from $48 and keeps an Overweight rating on the shares. While the Street is modeling a high probability…
Celldex price target lowered to $61 from $67 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Celldex (CLDX) to $61 from $67 and keeps an Overweight rating on the shares. Celldex’s Phase 2 barzolvolimab trial in prurigo nodularis…
Celldex price target lowered to $48 from $54 at Wells Fargo
Wells Fargo lowered the firm’s price target on Celldex (CLDX) to $48 from $54 and keeps an Overweight rating on the shares. While the firm removes PN from its model,…
Celldex price target lowered to $40 from $44 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Celldex (CLDX) to $40 from $44 and keeps an Overweight rating on the shares after the Phase 2 study of barzolvolimab in…
Celldex price target lowered to $60 from $62 at Canaccord
Canaccord lowered the firm’s price target on Celldex (CLDX) to $60 from $62 and keeps a Buy rating on the shares. The firm updated its model after the company reported…